NEWS

Quotient Sciences Announces Multimillion-Pound Investment in Drug Substance Manufacturing Facility

Read article

Events

AAPS PharmSci 360 2021

17 October 2021 - 20 October 2021
Connect with Quotient Sciences at the upcoming AAPS PharmSci 360 from October 17-20, 2021 in Philadelphia, PA. We will be exhibiting at the in-person event in booth #319.  Our experts will be on hand to discuss your drug development needs and update you on our expanded capabilities. To schedule a meeting with our team at the event, email: info@quotientsciences.com

Access our On Demand talk during the conference featuring Quotient's Senior Research Fellow, Dr Shriram Pathak, entitled: "Development and Characterization of Pediatric Formulations: Industrial Challenges and Solutions"- https://www.eventscribe.net/2021/PharmSci360/index.asp?presTarget=1695386

Presentation Overview:

The development of safe, effective and most importantly acceptable and palatable pediatric formulations has become a key requirement for pharma and biotech companies. Pediatric product development however is much more than just an allometric scaling down of an adult dose and poses unique challenges for the development teams, e.g. the wide age range of pediatric population (0-18 years) may elicit the need of multiple product formats and/or flexible formulation strategies to cater to the varying requirements of the pediatric patients such as swallowability, size of dosage form and palatability. Expert knowledge when choosing excipient type and levels is crucial to ensure patient safety and regulatory approval. Moreover, the formulators also need to factor-in the caregivers’ needs in terms of ease and method of administration. Eventually, fulfilling these diversified design requirements and ensuring that the product still complies with the stringent regulatory guidelines is a critical challenge within the industry today.


This presentation will introduce the current state of knowledge and highlight the unique challenges industry is currently facing in developing customized dosage forms for pediatric patients, challenges which can be magnified given the biopharmaceutics and often aversive properties of today’s drug substance chemistry. This session will also focus on the unmet formulation needs highlighting how improved understanding of pediatric formulations in terms of dosage form design flexibility, limited excipient portfolio, taste masking and assessment, relevant in vitro product characterization techniques and ever evolving regulatory requirements can have a direct bearing on the pediatric drug development programmes.
The presentation will include case studies demonstrating how an optimum use of in vitro, in-silico and clinical taste and PK assessments can give formulators an edge to drive pediatric drug development programmes in a more systematic and efficient way, ultimately reducing the overall product development timelines.

Learning Objectives:
-Highlight the current knowledge gaps and critical challenges within pediatric formulation development programmes and help exchanging of ideas to move this fundamental science further.
-Appreciate the value and purpose of key product characterisation techniques- in vitro, in-silico (viz. PBPK) and clinical taste/PK studies in pediatric drug product development.
-Support building a rational and patient centric product development with a holistic understanding of the special needs of this population and their caregivers.


At AAPS, Quotient's scientists will also be virtually presenting four scientific posters.  If you would like a copy of any of these posters, please let us know by emailing info@quotientsciences.com and we can send it over once the conference has begun. 


  • Development of a Modified Release Matrix Tablet Formulation Using Solid Lipid Compritol® 888 for a Poorly Soluble Drug
    -Presenting author: Dolly Jacob, Head of Development at Quotient Sciences
    -
    Virtual presentation on Wednesday, Oct. 20th at 12:30pm
  • ​​​​​​Development and Application of a PBPK Model Using Theoretical Particle Size Distribution to Describe in vivo Dissolution to Predict the Impact of Formulation Changes on Oral Bioavailability of GB001
    -Presenting author: Dr Krishna Machavaram, Senior Reserach Fellow at Quotient Sciences
    -
    Virtual presentation on Wednesday, Oct. 20th at 12:30pm
  • Pharmaceutical and Clinical Performance Comparisons of Modified Release Multiparticulates and Matrix Tablet Formulations
    -Presenting author: Dr Asma Patel, Executie Director of Product Development, Quotient Sciences
    -
    Virtual presentation on Monday, Oct. 18th at 8:00am 
  • Influence of Drug Loading and Fillers on Drug Release from HPMC Matrix Tablets
    -Presenting author: Dr Wu Lin, Senior Research Fellow at Quotient Sciences
    -
    Virtual presentation on Wednesday, Oct. 20th at 8:00am

Event details:

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.